Clinical Trial Update: Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating a vaccine therapy with pembrolizumab for hormone-resistant metastatic prostate cancer completed with posted results in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Vaccine therapy

Snippet

Sponsor: University of Wisconsin, Madison | Conditions: Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-12-01